Jasper Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc. filed a Current Report on Form 8-K dated January 18, 2023, with the report signed on January 19, 2023. The filing reports a Nasdaq listing compliance matter under Item 8.01, Other Events.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Change Versus Prior Period
Jasper received notice from Nasdaq that it had regained full compliance with Nasdaq Capital Market Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
Compliance was restored after the Company’s common stock closing bid price remained at or above $1.00 for ten consecutive business days, from January 3 through January 17, 2023.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. Regaining compliance removes the reported minimum bid price deficiency as of the notice date; however, the Company must continue satisfying Nasdaq’s ongoing listing requirements.
Investor Verification Points
- Verify the Nasdaq notice date and the ten-business-day compliance period.
- Confirm that the common stock closing bid price remained at or above $1.00 from January 3 through January 17, 2023.
- Review subsequent filings for any additional Nasdaq compliance issues or listing developments.
- Review the Company’s periodic reports for current liquidity, financing needs, operating results, and other financial risks, which are not addressed in this filing.